- 中国精品科技期刊
- 中国高校百佳科技期刊
- 中国中文核心期刊
- 中国科学引文数据库核心期刊
| Citation: |
ZENG Hao, WU Guozhen, ZOU Wuxin, et al. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. J China Pharm Univ, 2024, 55(3): 326 − 334. DOI: 10.11665/j.issn.1000-5048.2024040904
|
The new generation of artificial intelligence technology, represented by deep learning, has emerged as a crucial driving force in the advancement of new drug research and development. This article creatively proposes a workflow named “Molecular Factory” for the design and optimization of drug molecules based on artificial intelligence technology. This workflow integrates intelligent molecular generation models, high-performance molecular docking algorithms, and accurate protein-ligand binding affinity prediction methods. It has been integrated as a core module into DrugFlow, a one-stop drug design software platform, providing a comprehensive set of mature solutions for the discovery and optimization of lead compounds. Utilizing the “Molecular Factory” module, we conducted the research of second-generation inhibitors against Menin that can combat drug resistance. Through the integration of computational and experimental approaches, we rapidly identified multiple promising compounds. Among them, compound RG-10 exhibited the IC50 values of 9.681 nmol/L, 233.2 nmol/L, and 40.09 nmol/L against the wild-type Menin, M327I mutant, and T349M mutant, respectively. Compared to the positive reference molecule SNDX-5613, which has entered Phase II clinical trials, RG-10 demonstrated significantly enhanced inhibitory activity against the M327I and T349M mutants. These findings fully demonstrate the unique advantages of the "Molecular Factory" technology in practical drug design and development scenarios. It can rapidly and efficiently generate high-quality active molecules targeting specific protein structures, holding significant value and profound implications for advancing new drug discovery.
| [1] |
Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes[J]. Cancer Cell, 2008, 14(1): 36-46. doi: 10.1016/j.ccr.2008.05.003
|
| [2] |
Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia[J]. Nature, 2023, 615(7954): 920-924. doi: 10.1038/s41586-023-05812-3
|
| [3] |
Perner F, Stein EM, Wenge DV, et al. MEN1 mutations mediate clinical resistance to menin inhibition[J]. Nature, 2023, 615(7954): 913-919. doi: 10.1038/s41586-023-05755-9
|
| [4] |
Grisham J. Menin Inhibitors: Promising New Drug Treatment for Aggressive Leukemia | Memorial Sloan Kettering Cancer Center[EB/OL]. (2023-03-15)[2024-03-22]. https://www.mskcc.org/news/promising-new-type-drug-aggressive-leukemia.
|
| [5] |
Cavasotto CN, di Filippo JI. Artificial intelligence in the early stages of drug discovery[J]. Arch Biochem Biophys, 2021, 698: 108730. doi: 10.1016/j.abb.2020.108730
|
| [6] |
Gupta R, Srivastava D, Sahu M, et al. Artificial intelligence to deep learning: machine intelligence approach for drug discovery[J]. Mol Divers, 2021, 25(3): 1315-1360. doi: 10.1007/s11030-021-10217-3
|
| [7] |
Zhang O, Zhang JT, Jin JY, et al. ResGen is a pocket-aware 3D molecular generation model based on parallel multiscale modelling[J]. Nat Mach Intell, 2023, 5: 1020-1030. doi: 10.1038/s42256-023-00712-7
|
| [8] |
Zhang HT, Zhao HF, Zhang XJ, et al. Delete: deep lead optimization enveloped in protein pocket through unified deleting strategies and a structure-aware network[EB/OL]. arXiv, 2023: 2308.02172. http://arxiv.org/abs/2308.02172.
|
| [9] |
Xiong GL, Wu ZX, Yi JC, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties[J]. Nucleic Acids Res, 2021, 49(W1): W5-W14. doi: 10.1093/nar/gkab255
|
| [10] |
Jiang DJ, Lei TL, Wang Z, et al. ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning[J]. J Cheminform, 2020, 12(1): 16. doi: 10.1186/s13321-020-00421-y
|
| [11] |
Adasme MF, Linnemann KL, Bolz SN, et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA[J]. Nucleic Acids Res, 2021, 49(W1): W530-W534. doi: 10.1093/nar/gkab294
|
| [12] |
Hain E, Camacho CJ, Koes DR. Fragment oriented molecular shapes[J]. J Mol Graph Model, 2016, 66: 143-154. doi: 10.1016/j.jmgm.2016.03.017
|
| [13] |
Nicholls A, McGaughey GB, Sheridan RP, et al. Molecular shape and medicinal chemistry: a perspective[J]. J Med Chem, 2010, 53(10): 3862-3886. doi: 10.1021/jm900818s
|
| [14] |
Koes DR, Camacho CJ. Shape-based virtual screening with volumetric aligned molecular shapes[J]. J Comput Chem, 2014, 35(25): 1824-1834. doi: 10.1002/jcc.23690
|
| [15] |
Muhammed MT, Aki-Yalcin E. Molecular docking: principles, advances, and its applications in drug discovery[J]. Lett Drug Design Discov, 2024, 21(3): 480-495.
|
| [16] |
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading[J]. J Comput Chem, 2010, 31(2): 455-461. doi: 10.1002/jcc.21334
|
| [17] |
Eberhardt J, Santos-Martins D, Tillack AF, et al. AutoDock vina 1.2. 0: new docking methods, expanded force field, and python bindings[J]. J Chem Inf Model, 2021, 61(8): 3891-3898. doi: 10.1021/acs.jcim.1c00203
|
| [18] |
Zhang XJ, Zhang O, Shen C, et al. Efficient and accurate large library ligand docking with KarmaDock[J]. Nat Comput Sci, 2023, 3(9): 789-804. doi: 10.1038/s43588-023-00511-5
|
| [19] |
Cai H, Shen C, Jian TY, et al. CarsiDock: a deep learning paradigm for accurate protein-ligand docking and screening based on large-scale pre-training[J]. Chem Sci, 2024, 15(4): 1449-1471. doi: 10.1039/D3SC05552C
|
| [20] |
Shen C, Zhang XJ, Deng YF, et al. Boosting protein-ligand binding pose prediction and virtual screening based on residue-atom distance likelihood potential and graph transformer[J]. J Med Chem, 2022, 65(15): 10691-10706. doi: 10.1021/acs.jmedchem.2c00991
|
| [1] | ZHANG Zhixing, DENG Hua, TANG Yun. Applications and challenges of artificial intelligence in the development of anticancer peptides[J]. Journal of China Pharmaceutical University, 2024, 55(3): 347-356. DOI: 10.11665/j.issn.1000-5048.2024040201 |
| [2] | HU Zi’ang, GAO Liming, YU Wenying. Advances in the application of artificial intelligence in nucleic acid drug development[J]. Journal of China Pharmaceutical University, 2024, 55(3): 335-346. DOI: 10.11665/j.issn.1000-5048.2024033101 |
| [3] | ZENG Hao, WU Guozhen, ZOU Wuxin, WANG Zhe, SONG Jianfei, SHI Hui, WANG Xiaojian, HOU Tingjun, DENG Yafeng. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. Journal of China Pharmaceutical University, 2024, 55(3): 326-334. DOI: 10.11665/j.issn.1000-5048.2024040904 |
| [4] | CHEN Baiyu, LYU Lunan, XU Xiaodi, ZHANG Ying, LI Wei, FU Wei. Reflections on improving drug success rates with AIDD and CADD[J]. Journal of China Pharmaceutical University, 2024, 55(3): 284-294. DOI: 10.11665/j.issn.1000-5048.2024011302 |
| [5] | PU Chengtao, GU Lingqian, CHEN Xingye, ZHANG Yanmin. Prediction of human intestinal absorption properties based on artificial intelligence[J]. Journal of China Pharmaceutical University, 2023, 54(3): 355-362. DOI: 10.11665/j.issn.1000-5048.2023032102 |
| [6] | XUE Feng, FENG Shuo, LI Jing. Application and prospect of artificial intelligence in antimicrobial peptides screening[J]. Journal of China Pharmaceutical University, 2023, 54(3): 314-322. DOI: 10.11665/j.issn.1000-5048.2023030901 |
| [7] | GU Zhihao, GUO Wenhao, YAO Hequan, LI Xuanyi, LIN Kejiang. Research progress of the screening and generation of lead compounds based on artificial intelligence model[J]. Journal of China Pharmaceutical University, 2023, 54(3): 294-304. DOI: 10.11665/j.issn.1000-5048.2023042201 |
| [8] | YU Zehao, ZHANG Leiming, ZHANG Mengna, DAI Zhiqi, PENG Chengbin, ZHENG Siming. Artificial intelligence-based drug development: current progress and future challenges[J]. Journal of China Pharmaceutical University, 2023, 54(3): 282-293. DOI: 10.11665/j.issn.1000-5048.2023041003 |
| [9] | WANG Chao, XIAO Fu, LI Miaozhu, PAN Ying, DING Xiao, REN Feng, ZHAVORONKOV Alex, WANG Yazhou. Application progress of artificial intelligence in the screening and identification of drug targets[J]. Journal of China Pharmaceutical University, 2023, 54(3): 269-281. DOI: 10.11665/j.issn.1000-5048.2023041102 |
| [10] | YAN Fangrong. Application and advance of artificial intelligence in biomedical field[J]. Journal of China Pharmaceutical University, 2023, 54(3): 263-268. DOI: 10.11665/j.issn.1000-5048.2023030304 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Total visits：292830
DownLoad: